Shifting Thresholds
Adoption of the 2025 American College of Cardiology/American Heart Association guideline results in a minimal expansion of antihypertensive treatment eligibility. Results were robust across PREVENT model variants, supporting risk-based guideline implementation.
Authors
- Bede N. Nriagu (ORCID: https://orcid.org/0000-0003-3006-4796)
- Yaa A. Kwapong (ORCID: https://orcid.org/0000-0001-8459-291X)
- Lily N Dastmalchi
- Samuel E. McCoy
- Carl J. Ade (ORCID: https://orcid.org/0000-0002-1837-2342)
- Faith Metlock (ORCID: https://orcid.org/0000-0001-6005-1844)
- Britton Scheuermann
- Jared Spitz (ORCID: https://orcid.org/0009-0005-3233-7833)
- Stephen Juraschek
- Garima Sharma
- Alexander C. Razavi
Institutions
- Inova Health System (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Johns Hopkins University (US)
- Emory University (US)
- Kansas State University (US)
- Johns Hopkins Medicine (US)
- Emory Clinic (US)
Publication Details
- Journal
- JACC Advances
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1016/j.jacadv.2025.102546
- Primary Topic
- Blood Pressure and Hypertension Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00